TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced non small cell lung cancer (NSCLC): Phase IIb results of the TIME trial
نویسندگان
چکیده
TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced non small cell lung cancer (NSCLC): Phase IIb results of the TIME trial John Nemunaitis, Zsolt Papai, Hervé Léna, Gyorgy Losonczy, Frederic Forget, Christos Chouaid, Alexandra Szczesna, Radj Gervais, Christian H Ottensmeier, Joseph Beck, Andrzej Kazarnowicz, Virginie Westeel, Didier Debieuvre, Anne Madroszyk, Enriqueta Felip, Jean Marc Limacher, Elisabeth Quoix
منابع مشابه
TG4010 immunotherapy combined with first-line therapy in advanced non-small cell lung cancer (NSCLC): phase IIb results of the TIME study
TG4010 immunotherapy combined with first-line therapy in advanced non-small cell lung cancer (NSCLC): phase IIb results of the TIME study Elisabeth Quoix, Lecia Sequist, John Nemunaitis, Thaddeus Beck, Piotr Jaskiewicz, Jean-Philippe Oster, Arnaud Scherpereel, Erzsébet Juhász, Zsuzsanna Mark, Rosa Alvarez, Saiama Waqar, Joseph Potz, Nandagopal Vrindavanam, Anton Melnyk, Helen Ross, Jean-Marc Li...
متن کاملImpact of TG4010 Vaccine on Health-Related Quality of Life in Advanced Non-Small-Cell Lung Cancer: Results of a Phase IIB Clinical Trial
BACKGROUND This study describes the effect of TG4010 vaccine on Health related Quality of Life (HRQOL) in patients with stage IIIb and IV non-small-cell lung cancer (NSCLC). METHODS 148 patients with advanced NSCLC expressing MUC1 were randomly assigned to receive TG4010 plus chemotherapy or chemotherapy alone. HRQOL was assessed with the Functional Assessment of Cancer Therapy-Lung (FACT-L) ...
متن کاملViral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC
BACKGROUND Advanced non-small cell lung cancer patients receiving TG4010, a therapeutic viral vaccine encoding human Mucin 1 and interleukin-2 in addition to standard chemotherapy, displayed longer overall survival in comparison to that of patients treated with standard chemotherapy alone. Our study intended to establish the association between overall survival and vaccine-induced T cell respon...
متن کاملTg4010 Vaccine Targeting on NSCLC
Lung cancer is the most common factor of cancer-related deaths and about 85% of lung cancer is non-small cell lung cancer (NSCLC). MUC1, known as the attached protein or trans-membrane protein, is a kind of protein with highly glycosylation (greater than 50%) and high molecular weight (Mr>200*103). MUC1 is overexpressed in many malignancies, and as a tumor-associated antigens (TAAs), it exposes...
متن کاملA phase II study of first-line chemotherapy with weekly carboplatin plus gemcitabine in advanced non-small cell lung cancer.
BACKGROUND The efficacy and safety of weekly carboplatin (CBDCA) and gemcitabine (GEM) was evaluated as first-line chemotherapy with advanced non-small cell lung cancer (NSCLC). METHODS 46 chemotherapy-naive patients with measurable NSCLC were enrolled. Patients underwent a combination chemotherapy of GEM 1,000 mg/m2 plus CBDCA at an area under the curve of 2 on days 1 and 8 every 3 weeks. ...
متن کامل